05/01/2026
Dr. Emma Guttman-Yassky and team, with first author Dr. Kazuhiko Yamamura and research fellow Jerry Zhou, uncover a lipid-driven immune mechanism shaping atopic dermatitis in Allergy 🧬✨ This study identifies sphingosine-1-phosphate, S1P, signaling as a key regulator of Th2 and Th9 inflammation, showing that S1P markedly increases IL-13 and IL-9 production in CD4+ T cells. Mechanistically, the work reveals a striking reciprocal axis, S1PR1 promotes these pathogenic cytokines, while S1PR5 suppresses them. In lesional skin and circulating immune cells from patients with atopic dermatitis, S1PR5 expression is significantly reduced, while S1PR1 activity remains preserved, creating a pro-inflammatory imbalance that sustains disease. Notably, as shown in the cytokine assays on page six and receptor expression analyses on page seven, S1P exposure drives IL-13 and IL-9 to levels seen in patients, directly linking lipid signaling to disease biology. 🔬🧪
đź“š https://bit.ly/48smjrf
Watch the YouTube video here! 🎥 https://bit.ly/41YXIH1
These findings matter because they move beyond cytokines alone and position lipid mediators as upstream drivers of immune dysregulation in atopic dermatitis. By defining how S1PR1 and S1PR5 exert opposing control over key disease cytokines, this work provides a mechanistic foundation for emerging S1P-targeted therapies already in development. Rather than broadly suppressing inflammation, modulating this pathway offers a route to recalibrate immune balance at the level of T cell signaling. This study reinforces Mount Sinai’s leadership in translational Dermatology, bridging immunology and therapeutic innovation, and challenging us to think more broadly about the drivers of chronic inflammatory skin disease. 🧠🧴
